ClinicalTrials.gg
CompletedNCT05285137Updated Feb 27, 2025Results posted

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

A Phase 1 interventional study of CD388 Injection and Saline placebo in Healthy, sponsored by Cidara Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Cidara Therapeutics Inc. (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this first-in-human study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when administered as a single dose to healthy adult subjects by injection either in the muscle or under the skin.

Read the detailed description

A Phase 1, single-center, prospective, randomized, double-blind, single-dose and repeat single-dose, dose-escalation study to determine the safety, tolerability, and pharmacokinetics of CD388 Injection, as compared to saline placebo, when dosed either by intramuscular (IM) or subcutaneous (SQ) administration to healthy adult subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Cidara Therapeutics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written .
  2. Males and females 18 to 65 years of age, inclusive.
  3. A female subject must meet one of the following criteria:

    1. If of - agrees to use a highly effective, preferably user-independent method of (failure rate of \<1 percent per year when used consistently and correctly) for at least 30 days prior to screening and agrees to remain on a highly effective method until 205 days after last dose of study medication. Examples of highly-effective methods of contraception include: abstinence from heterosexual intercourse; hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch); intrauterine device (with or without hormones); or a double barrier method (e.g., condom and spermicide).
    2. If a female of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by follicle-stimulating hormone (FSH) levels (≥40 milli-International units [mIU]/milliliter [mL]).
  4. A woman of childbearing potential must have a negative highly sensitive serum pregnancy test (β-human chorionic gonadotropin) at screening and a negative urine pregnancy test on Day -1 before the first dose of study drug.
  5. A male subject that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and until at least 205 days after the last dose of the study medication.
  6. Good health and without signs or symptoms of current illness.
  7. Normal clinical examination, including:

    1. No physical examination findings that an Investigator determines would interfere with interpretation of study results.
    2. Screening without abnormalities.
    3. (CrCL) ≥80 mL/minute as calculated using the Cockcroft-Gault equation.
    4. Negative urine screen for drugs of abuse and alcohol at screening and Day -1.
  8. (BMI; weight in kilograms [kg] divided by height in meters [m] squared) between 18.0 and 32.0 kg/m\^2, inclusive.
  9. Willing to refrain from strenuous physical activity that could cause muscle aches or injury, including contact sports, at any time from screening through 30 days after any dose of study drug.
  10. Subject has adequate venous access for blood collection.

Exclusion criteria

Exclusion Criteria:

  1. History of any or allergic reaction to zanamivir or other neuraminidase inhibitors (i.e., laninamivir, oseltamivir, peramivir), or to of the CD388 Injection drug formulation; or history of drug-induced exfoliative skin disorders (e.g., Stevens-Johnson syndrome [SJS], erythema multiforme, or toxic epidermal necrolysis [TEN]).
  2. History of any of the following:

    1. Allergies, anaphylaxis, skin rashes (foods such as milk, eggs, medications, vaccines, polyethylene glycol [PEG], etc.).
    2. Chronic immune-mediated disease, positive first-degree family history of diseases.
    3. Atopic dermatitis or psoriasis.
    4. Bleeding disorder.
    5. Psychiatric condition, seizures, hallucinations, anxiety, depression, or treatment for mental conditions.
    6. Migraines.
    7. Syncope, or vasovagal syndrome with injections or blood draws.
    8. Cardiac arrhythmia.
  3. Subjects with one or more of the following laboratory abnormalities at screening as defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events v2.1 (DAIDS 2017):

    1. Serum creatinine, Grade ≥1 (≥1.1 × [ULN])
    2. Pancreatic amylase or lipase, Grade ≥2 (≥1.5 × ULN)
    3. (AST) or alanine aminotransferase (ALT), Grade ≥1 (≥1.25 × ULN)
    4. Total , Grade ≥1 (≥1.1 × ULN)
    5. Any other toxicity Grade ≥2, except for Grade 2 elevations of triglycerides, low density lipoprotein cholesterol, and/or total cholesterol.
    6. Any other laboratory abnormality considered to be by the Investigator.

    Note: Retesting of abnormal laboratory values that may lead to exclusion will be allowed once without prior asking approval from the Sponsor. Retesting will take place during a scheduled or unscheduled visit during screening. Subjects with a normal value at retest may be included.

  4. Alcohol or drug addiction in the past 2 years.
  5. Experiencing symptoms of acute illness or chronic disease within 14 days prior to check-in to the clinical research unit (CRU).
  6. At screening, a positive result for virus surface antigen, virus antibody, or (HIV) antibody.
  7. A positive result at screening or CRU check-in for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction (PCR). Beginning with Protocol Amendment 2, antigen testing may be used if PCR is not available.
  8. Unwilling to comply with local health policy effective at the time regarding coronavirus disease 2019 (COVID-19).*
  9. Women who are pregnant or nursing.
  10. Received any over-the-counter (OTC) medications or nutritional supplements within 7 days, or any prescription medications within 14 days or \<5 half-lives prior to dosing.
  11. Current nicotine user or has quit habitual nicotine use in the 30 days prior to screening.
  12. Received any vaccines or immunoglobulins within 28 days prior to dosing (90 days in case of intravenous immunoglobulin [IVIg] or biologics, or 14 days for COVID-19 vaccine).**
  13. Donated blood (within 56 days of screening) or plasma (within 7 days of screening) or experienced significant blood loss or significant blood draw when participating in non-interventional clinical trials within 60 days prior to dosing.
  14. Received a blood transfusion within 28 days prior to dosing.
  15. Received any biologics within 90 days prior to dosing. Previous participation in another study within 30 days or 5 half-lives of the study drug, whichever is longer, prior to screening; prior participation at any time in non-invasive methodology trials in which no drugs were given is acceptable.
  16. The PI considers that the volunteer should not participate in the study.

(*) Full COVID-19 vaccination prior to participation is strongly recommended.

(**) In the event a subject chooses to receive one of the two 2-dose approved or emergency-use-authorized COVID 19 vaccines (Comirnaty® [Pfizer], Spikevax™ [Moderna]) in the interval between two CRU stays (Cohort 2A/2B or Cohort 3A/3B), flexibility in timing of the second CRU stay should be applied, to allow appropriate receipt of the second vaccine dosage or booster (based on the respective vaccine label) + 14 days, to minimize risk of confounding findings/observations.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Cohort 1A (sentinel)

    Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 1A (main)

    Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 1B (sentinel)

    Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 1B (main)

    Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 2A (sentinel)

    Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 2A (main)

    Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 2B (sentinel)

    Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 2B (main)

    Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 3A (sentinel)

    High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 3A (main)

    High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 3B (sentinel)

    High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 3B (main)

    High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 4B (sentinel)

    Highest dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 4B (main)

    Highest dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection

    Combination Product: CD388 Injection · Drug: Saline placebo

Interventions

  • Combination productCD388 Injection

    CD388 liquid for injection

  • DrugSaline placebo

    Sterile normal saline for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388

    Number of participants with at least one TEAE, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

    Time frame: Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)

  2. Severity of TEAEs After a Single Dose of CD388

    Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

    Time frame: Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)

Secondary outcomes

  1. Mean Peak Plasma Concentration (Cmax) Following a Single Administration of CD388

    Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  2. Median Peak Plasma Concentration (Cmax) Following a Single Administration of CD388

    Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  3. Mean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388

    Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  4. Median Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388

    Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  5. Mean Terminal Elimination Half-life (t½) Following a Single Administration of CD388

    Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  6. MedianTerminal Elimination Half-life (t½) Following a Single Administration of CD388

    Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  7. Mean Apparent Clearance (CL/F) Following a Single Administration of CD388

    Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  8. Median Apparent Clearance (CL/F) Following a Single Administration of CD388

    Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  9. Mean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388

    Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  10. Median Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388

    Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  11. Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  12. Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  13. Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  14. Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.

    Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

  15. Mean Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388

    Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  16. Median Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388

    Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  17. Mean Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388

    Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  18. Median Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388

    Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  19. Mean Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388

    Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  20. Median Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388

    Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  21. Mean Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388

    Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  22. Median Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388

    Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  23. Mean Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388

    Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  24. Median Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388

    Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  25. Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  26. Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  27. Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  28. Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388

    Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

    Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)

  29. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Repeated Single Dose of CD388

    Number of participants with at least one TEAE, including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.

    Time frame: Day 207 through Day 412 (±10 days) (Cohorts 2A/2B and 3A/3B only)

  30. Severity of TEAEs After a Repeated Single Dose of CD388

    Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.

    Time frame: Day 207 through Day 412 (±10 days) (Cohorts 2A/2B and 3A/3B only)

07

Results

Posted Jan 24, 2025

Participant flow

A total of 77 participants were enrolled in the study at a single center, 33 of whom were randomized to receive study drug via intramuscular (IM) administration and 44 of whom were randomized to receive study drug via subcutaneous (SQ) administration.

Participant flow — Overall Study
MilestoneCD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQ
Started8889888812
Completed8655884810
Not completed023400402
Withdrew: Failure to meet continuation criteria000000201
Withdrew: Lost to follow-up001300100
Withdrew: Physician decision010000000
Withdrew: Pregnancy000000100
Withdrew: Withdrawal by subject012100001

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388

Number of participants with at least one TEAE, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Time frame:
Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388
ParticipantsCD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQ
Participants with at least one TEAE555854537
Participants with AEs leading to study withdrawal000000200
PrimarySeverity of TEAEs After a Single Dose of CD388

Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Time frame:
Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)
Reported as:
Count of participants · Participants
Severity of TEAEs After a Single Dose of CD388
ParticipantsCD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQ
Mild552544336
Moderate003210101
Severe000100100
SecondaryMean Peak Plasma Concentration (Cmax) Following a Single Administration of CD388

Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Mean · micrograms/milliliter (ug/mL)
Mean Peak Plasma Concentration (Cmax) Following a Single Administration of CD388
micrograms/milliliter (ug/mL)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Mean Peak Plasma Concentration (Cmax) Following a Single Administration of CD3884.13 ± 0.74710.4 ± 2.4448.6 ± 11.73.57 ± 0.94212.0 ± 3.3532.7 ± 9.4058.8 ± 17.5
SecondaryMedian Peak Plasma Concentration (Cmax) Following a Single Administration of CD388

Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Median · micrograms/milliliter (ug/mL)
Median Peak Plasma Concentration (Cmax) Following a Single Administration of CD388
micrograms/milliliter (ug/mL)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Median Peak Plasma Concentration (Cmax) Following a Single Administration of CD3883.96 (2.91 to 5.34)10.4 (6.52 to 13.6)48.0 (35.2 to 67.7)3.72 (2.17 to 4.83)11.8 (6.84 to 17.0)31.6 (16.6 to 48.0)60.7 (34.3 to 91.3)
SecondaryMean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388

Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Mean · hours (h)
Mean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388
hours (h)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Mean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388111.08 ± 72.42159.03 ± 83.1085.64 ± 42.19213.00 ± 108.43137.48 ± 77.82120.04 ± 67.83109.54 ± 55.66
SecondaryMedian Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388

Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Median · hours (h)
Median Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388
hours (h)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Median Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD38896.07 (48.17 to 240.00)131.98 (71.97 to 312.00)78.31 (24.17 to 144.00)228.00 (72.00 to 312.02)131.28 (48.22 to 312.02)96.00 (48.17 to 240.00)96.00 (48.17 to 192.00)
SecondaryMean Terminal Elimination Half-life (t½) Following a Single Administration of CD388

Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Mean · hours (h)
Mean Terminal Elimination Half-life (t½) Following a Single Administration of CD388
hours (h)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Mean Terminal Elimination Half-life (t½) Following a Single Administration of CD3881234.41 ± 140.041192.03 ± 235.801006.20 ± 314.391069.78 ± 216.481265.53 ± 223.931065.21 ± 239.191384.36 ± 282.53
SecondaryMedianTerminal Elimination Half-life (t½) Following a Single Administration of CD388

Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Median · hours (h)
MedianTerminal Elimination Half-life (t½) Following a Single Administration of CD388
hours (h)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
MedianTerminal Elimination Half-life (t½) Following a Single Administration of CD3881275.62 (985.09 to 1390.45)1285.85 (783.24 to 1471.71)1137.42 (540.88 to 1384.09)1052.39 (685.81 to 1350.50)1270.40 (796.65 to 1576.21)1040.30 (809.64 to 1502.38)1287.45 (1110.87 to 1998.04)
SecondaryMean Apparent Clearance (CL/F) Following a Single Administration of CD388

Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Mean · liters/hour (L/h)
Mean Apparent Clearance (CL/F) Following a Single Administration of CD388
liters/hour (L/h)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Mean Apparent Clearance (CL/F) Following a Single Administration of CD3880.00751 ± 0.001190.00867 ± 0.001770.00766 ± 0.001990.00900 ± 0.002300.00725 ± 0.001230.00883 ± 0.002130.00863 ± 0.00158
SecondaryMedian Apparent Clearance (CL/F) Following a Single Administration of CD388

Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Median · liters/hour (L/h)
Median Apparent Clearance (CL/F) Following a Single Administration of CD388
liters/hour (L/h)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Median Apparent Clearance (CL/F) Following a Single Administration of CD3880.00707 (0.00614 to 0.00991)0.00851 (0.00640 to 0.0112)0.00726 (0.00571 to 0.0116)0.00834 (0.00591 to 0.0128)0.00717 (0.00551 to 0.00909)0.00912 (0.00493 to 0.0115)0.00870 (0.00648 to 0.0111)
SecondaryMean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388

Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Mean · liters (L)
Mean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388
liters (L)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Mean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD38813.3 ± 1.9114.8 ± 4.4010.7 ± 2.9913.4 ± 2.5913.3 ± 3.7013.1 ± 2.6117.1 ± 3.76
SecondaryMedian Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388

Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Median · liters (L)
Median Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388
liters (L)Cohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Median Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD38813.9 (10.3 to 15.8)14.4 (11.1 to 23.9)10.9 (6.47 to 15.1)12.2 (11.4 to 18.7)12.7 (9.27 to 20.7)12.9 (10.7 to 18.9)16.7 (11.2 to 24.2)
SecondaryMean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Mean · ug*h/mL
Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388
ug*h/mLCohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD3885450 ± 72815000 ± 432053800 ± 120004830 ± 96518800 ± 336049000 ± 1310096300 ± 16700
SecondaryMedian Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Median · ug*h/mL
Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388
ug*h/mLCohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD3885460 (4410 to 6530)15100 (7250 to 21100)52100 (37600 to 71200)4960 (3270 to 6300)18700 (13700 to 24400)46500 (34800 to 76600)94700 (71700 to 121000)
SecondaryMean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Mean · ug*h/mL
Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388
ug*h/mLCohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD3886790 ± 97317900 ± 367061800 ± 136005870 ± 147021200 ± 367054400 ± 16900107000 ± 19700
SecondaryMedian Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame:
Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Reported as:
Median · ug*h/mL
Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388
ug*h/mLCohort 1A CD388 50 mg IMCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 1B CD388 50 mg SQCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQCohort 4B CD388 900 mg SQ
Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD3887080 (5050 to 8140)17600 (13300 to 23400)62100 (38800 to 78800)6000 (3920 to 8470)21000 (16500 to 27200)49300 (39100 to 91400)103000 (80800 to 139000)
SecondaryMean Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388

Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Mean · micrograms/milliliter (ug/mL)
Mean Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388
micrograms/milliliter (ug/mL)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Mean Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD38810.5 ± 3.3028.8 ± 7.6613.0 ± 5.3431.1 ± 7.86
SecondaryMedian Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388

Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Median · micrograms/milliliter (ug/mL)
Median Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388
micrograms/milliliter (ug/mL)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Median Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD3889.94 (6.68 to 14.4)29.8 (18.0 to 38.3)12.5 (6.84 to 22.0)29.3 (23.8 to 43.8)
SecondaryMean Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388

Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Mean · hours (h)
Mean Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388
hours (h)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Mean Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388104.02 ± 81.25161.14 ± 75.53251.99 ± 200.79105.02 ± 49.89
SecondaryMedian Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388

Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Median · hours (h)
Median Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388
hours (h)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Median Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD38884.00 (48.00 to 264.00)144.00 (48.00 to 264.00)227.99 (48.00 to 695.97)96.00 (47.07 to 167.00)
SecondaryMean Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388

Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Mean · hours (h)
Mean Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388
hours (h)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Mean Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD3881324.07 ± 198.331408.43 ± 336.721059.55 ± 409.511301.42 ± 83.00
SecondaryMedian Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388

Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Median · hours (h)
Median Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388
hours (h)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Median Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD3881342.81 (1108.91 to 1639.43)1506.38 (670.64 to 1721.28)1218.60 (508.57 to 1539.09)1348.40 (1175.81 to 1371.62)
SecondaryMean Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388

Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Mean · liters/hour (L/h)
Mean Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388
liters/hour (L/h)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Mean Apparent Clearance (CL/F) Following a Repeated Single Administration of CD3880.00923 ± 0.001230.00886 ± 0.001700.00802 ± 0.002180.00897 ± 0.00210
SecondaryMedian Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388

Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Median · liters/hour (L/h)
Median Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388
liters/hour (L/h)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Median Apparent Clearance (CL/F) Following a Repeated Single Administration of CD3880.00954 (0.00706 to 0.0104)0.00918 (0.00642 to 0.0105)0.00866 (0.00507 to 0.0116)0.00946 (0.00534 to 0.0106)
SecondaryMean Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388

Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Mean · liters (L)
Mean Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388
liters (L)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Mean Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD38817.4 ± 1.8517.8 ± 5.4511.7 ± 4.7016.7 ± 3.55
SecondaryMedian Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388

Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Median · liters (L)
Median Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388
liters (L)Cohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Median Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD38816.6 (15.4 to 20.2)16.7 (10.1 to 26.0)9.46 (7.45 to 19.2)18.3 (10.4 to 18.5)
SecondaryMean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Mean · ug*h/mL
Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388
ug*h/mLCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD38814400 ± 205041300 ± 1540018000 ± 509041100 ± 21100
SecondaryMedian Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Median · ug*h/mL
Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388
ug*h/mLCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD38813600 (12800 to 18000)41800 (13400 to 60600)16000 (12900 to 26600)39100 (13400 to 72700)
SecondaryMean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Mean · ug*h/mL
Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388
ug*h/mLCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD38816500 ± 253052600 ± 1080020000 ± 583053400 ± 17400
SecondaryMedian Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).

Time frame:
At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Reported as:
Median · ug*h/mL
Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388
ug*h/mLCohort 2A CD388 150 mg IMCohort 3A CD388 450 mg IMCohort 2B CD388 150 mg SQCohort 3B CD388 450 mg SQ
Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD38815700 (14500 to 21200)49000 (42900 to 70100)17300 (12900 to 29600)47600 (42300 to 84300)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Repeated Single Dose of CD388

Number of participants with at least one TEAE, including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.

Time frame:
Day 207 through Day 412 (±10 days) (Cohorts 2A/2B and 3A/3B only)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Repeated Single Dose of CD388
ParticipantsCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 150 mg SQCD388 450 mg SQPooled Placebo SQ
Participants with at least one TEAE242231
Participants with AEs leading to study withdrawal000000
SecondarySeverity of TEAEs After a Repeated Single Dose of CD388

Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.

Time frame:
Day 207 through Day 412 (±10 days) (Cohorts 2A/2B and 3A/3B only)
Reported as:
Count of participants · Participants
Severity of TEAEs After a Repeated Single Dose of CD388
ParticipantsCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 150 mg SQCD388 450 mg SQPooled Placebo SQ
Mild222231
Moderate020000
Severe000000

Adverse events

Collected over Adverse events were collected for all participants from the time of signing the informed consent form through the final study visit (Day 120 for the 50 mg dose arm [Cohorts 1A/1B]; Day 412 for the 150 mg and 450 mg dose arms [Cohorts 2A/2B and 3A/3B]; and Day 206 for the 900 mg dose arm [Cohort 4B]).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD388 50 mg IM0/8 (0%)0/8 (0%)5/8 (62.5%)
CD388 150 mg IM0/8 (0%)0/8 (0%)5/8 (62.5%)
CD388 450 mg IM0/8 (0%)0/8 (0%)6/8 (75%)
Pooled Placebo IM0/9 (0%)0/9 (0%)8/9 (88.9%)
CD388 50 mg SQ0/8 (0%)0/8 (0%)5/8 (62.5%)
CD388 150 mg SQ0/8 (0%)0/8 (0%)4/8 (50%)
CD388 450 mg SQ0/8 (0%)0/8 (0%)6/8 (75%)
CD388 900 mg SQ0/8 (0%)0/8 (0%)3/8 (37.5%)
Pooled Placebo SQ0/12 (0%)0/12 (0%)7/12 (58.3%)
Most frequent other events
Showing 10 of 65
Most frequent other events
EventCD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQ
HeadacheNervous system disorders0/82/82/84/95/80/82/80/82/12
Viral infectionInfections and infestations0/81/83/81/90/80/80/80/81/12
COVID-19Infections and infestations1/82/81/82/90/81/80/80/80/12
PresyncopeNervous system disorders0/80/80/80/90/82/80/80/81/12
Injection site painGeneral disorders0/80/81/82/90/80/80/80/81/12
Back painMusculoskeletal and connective tissue disorders0/80/80/82/90/81/81/80/80/12
CoughRespiratory, thoracic and mediastinal disorders0/81/80/82/90/80/80/80/80/12
DizzinessNervous system disorders0/80/80/81/90/80/80/80/82/12
NauseaGastrointestinal disorders0/81/81/81/90/80/80/80/81/12
VomitingGastrointestinal disorders0/80/80/80/91/80/80/80/81/12

Baseline characteristics

The Safety Population included all randomized participants who received any amount of study drug (77 total; 33 \[IM route\], 44 \[SQ route\]).

Age, Continuous
Age, Continuous(years)CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
Mean38.9 ± 7.7741.1 ± 12.8338.6 ± 12.7339.0 ± 15.5142.8 ± 12.5832.8 ± 10.7539.3 ± 14.9541.9 ± 13.9739.4 ± 13.8239.3 ± 12.62
Age, Continuous
Age, Continuous(years)CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
Median37.0 (30 to 55)38.5 (24 to 57)32.5 (28 to 63)30.0 (23 to 65)45.5 (21 to 56)30.5 (22 to 50)35.5 (19 to 62)34.0 (29 to 65)37.5 (18 to 59)35.0 (18 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
Female14153121523
Male74745767754
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
Hispanic or Latino0310011006
Not Hispanic or Latino857987781271
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
American Indian or Alaska Native0000000000
Asian0011000002
Native Hawaiian or Other Pacific Islander0000000000
Black or African American33344657843
White54434231430
More than one race0000000000
Unknown or Not Reported0101000002
Weight
Weight(kilograms (kg))CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
Mean86.19 ± 5.68079.53 ± 11.94579.51 ± 16.15779.97 ± 12.59683.15 ± 19.83581.03 ± 17.05385.28 ± 16.08586.30 ± 10.07976.73 ± 13.77581.67 ± 13.847
Weight
Weight(kg)CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
Median85.50 (77.6 to 95.3)80.40 (64.8 to 99.9)75.60 (63.0 to 105.9)80.90 (55.0 to 95.2)78.75 (59.9 to 112.5)78.20 (59.5 to 115.8)83.75 (64.1 to 118.6)87.90 (68.5 to 99.9)79.50 (55.4 to 101.7)81.70 (55.0 to 118.6)
Height
Height(centimeters)CD388 50 mg IMCD388 150 mg IMCD388 450 mg IMPooled Placebo IMCD388 50 mg SQCD388 150 mg SQCD388 450 mg SQCD388 900 mg SQPooled Placebo SQTotal
Mean178.88 ± 8.919172.25 ± 11.498174.50 ± 6.655172.00 ± 10.283173.38 ± 11.975172.38 ± 10.993172.00 ± 11.514176.19 ± 7.348171.17 ± 7.884173.49 ± 9.529

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Altasciences Clinical Kansas, Inc.
    Overland Park, Kansas 66212, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Oct 2023, 19 months.

Results were first posted in Jan 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2022
First posted
Mar 17, 2022
StartActual
Mar 14, 2022
Primary completionActual
Oct 27, 2023
CompletionActual
Oct 27, 2023
Results first posted
Jan 24, 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05285137
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Mar 14, 2022
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023
Results posted
Jan 24, 2025
Last update
Feb 27, 2025

Study contacts

Ozlem Equils, MD
study director · Cidara Therapeutics Inc.
Debra J Kelsh, MD
principal investigator · Altasciences Clinical Kansas, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion